King-Friend subsidiary gains FDA approval for new drug

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received US FDA approval for its new drug, fosfomycin for injection, 6g/vial. The drug is indicated for the treatment of complex urinary tract infections, including acute pyelonephritis, and to inhibit the development of drug-resistant bacteria. The company invested approximately RMB 47,211,000 in the research and development of this project.

The newly approved product is expected to launch in the US market soon, potentially boosting the company's operating performance. However, King-Friend also highlighted potential risks, including uncertain impacts from national policies and market conditions, which could lead to sales not meeting expectations. Investors are advised to exercise caution.

In related news, Nanjing King-Friend Biochemical Pharmaceutical will host a third-quarter earnings briefing on November 12, 2025, from 09:00 to 10:00, accessible via the Shanghai Stock Exchange Roadshow Center. This event follows the release of its Q3 2025 financial report, which showed a decrease in profit and net profit attributable to shareholders compared to the previous year.